DAX24.084 -0,2%Est505.860 -0,4%MSCI World4.343 -0,1%Top 10 Crypto9,5600 -4,4%Nas24.890 +0,2%Bitcoin65.324 -2,8%Euro1,1725 +0,1%Öl107,8 +1,8%Gold4.680 -0,6%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 NVIDIA 918422 SAP 716460 Siemens Energy ENER6Y Infineon 623100 Deutsche Telekom 555750 Lufthansa 823212 Amazon 906866 Siemens 723610 NEL ASA A0B733 AMD (Advanced Micro Devices) 863186 Mercedes-Benz Group (ex Daimler) 710000 Allianz 840400 Intel 855681 Novo Nordisk A3EU6F
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX letztlich schwächer -- US-Börsen wenig bewegt -- Aktien von SK hynix und TSMC brechen Rekorde -- NEL, Cavendish, Rüstungsaktien, E.ON, Allianz, Nordex, Tesla, VW, Commerzbank, Infineon im Fokus
Top News
Deutsche Börse-Aktie kaum verändert nach überaus gelungenem Jahresauftakt Deutsche Börse-Aktie kaum verändert nach überaus gelungenem Jahresauftakt
NVIDIA & Co. zum Schnäppchenpreis? Goldman Sachs prognostiziert Trendwende für "10er-Regel"-Aktien NVIDIA & Co. zum Schnäppchenpreis? Goldman Sachs prognostiziert Trendwende für "10er-Regel"-Aktien
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Theravance Biopharma Aktie

Kaufen
Verkaufen
Aktien-Sparplan anlegen
14,30 EUR +0,30 EUR +2,14 %
STU
16,78 USD +0,33 USD +2,01 %
BTT
finanzen.net zero
Theravance Biopharma jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.722,82 Mio. EUR

KGV9,10Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA1137V

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINKYG8807B1068

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolTBPH

Theravance Biopharma Aktien News

DatumMeistgelesen
PR NewswireTheravance Biopharma to Host Virtual KOL Investor Event to Review Ampreloxetine Phase 3 Clinical Development Program, Ahead of Topline Data in Q1 2026, on December 8, 2025
PR NewswireTheravance Biopharma to Participate in Upcoming Investor Conferences
PR NewswireTheravance Biopharma, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Wer­bungTheravance Biopharma-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
PR NewswireTheravance Biopharma to Present Data on Ampreloxetine at the 36th International Symposium on The Autonomic Nervous System
PR NewswireTheravance Biopharma to Report Third Quarter 2025 Financial Results on November 10, 2025
PR NewswireTheravance Biopharma to Present New Analyses Highlighting YUPELRI® (revefenacin) Outcomes in COPD at the 2025 CHEST Annual Meeting
PR NewswireTheravance Biopharma to Present at the H.C. Wainwright 27th Annual Global Investment Conference
PR NewswireTheravance Biopharma Completes Enrollment in Pivotal Phase 3 CYPRESS Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension due to Multiple System Atrophy
PR NewswireTheravance Biopharma, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update
PR NewswireTheravance Biopharma to Report Second Quarter 2025 Financial Results on August 12, 2025
PR NewswireTheravance Biopharma to Participate in an Upcoming Investor Conference
PR NewswireTheravance Biopharma Announces Approval of YUPELRI® (revefenacin) by China's NMPA
PR NewswireTheravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 Million
PR NewswireTheravance Biopharma to Participate in an Upcoming Investor Conference
PR NewswireTheravance Biopharma Announces Ampreloxetine Presentations at the International MSA Congress
PR NewswireTheravance Biopharma, Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update
PR NewswireTheravance to Present Analyses of Ampreloxetine and Neurogenic Orthostatic Hypotension at the 2025 International MSA Congress
PR NewswireTheravance Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025
PR NewswireTheravance Biopharma Presents Two New Ampreloxetine Analyses in Oral Session at the American Academy of Neurology 2025 Annual Meeting
PR NewswireTheravance Biopharma to Participate in an Upcoming Investor Conference
PR NewswireTheravance Biopharma to Present New Ampreloxetine Analyses in Neurogenic Orthostatic Hypotension (nOH) at the 77th Annual Meeting of the American Academy of Neurology
PR NewswireTheravance Biopharma, Inc. Reports Record Fourth Quarter and Full Year 2024 Financial Results
PR NewswireTheravance Biopharma to Participate in an Upcoming Investor Conference
PR NewswireTheravance Biopharma to Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025
PR NewswireTheravance Biopharma to Participate in an Upcoming Investor Conference
PR NewswireTheravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 43rd Annual Healthcare Conference
PR NewswireTheravance Biopharma to Participate in an Upcoming Investor Conference
PR NewswireTheravance Biopharma, Inc. Reports Third Quarter 2024 Financial Results and Announces Initiatives to Unlock Shareholder Value
PR NewswireTheravance Biopharma to Report Third Quarter 2024 Financial Results on November 12, 2024
PR NewswireTheravance Announces Publication of YUPELRI® (revefenacin) Area Under the Curve Spirometry Analysis in the International Journal of Chronic Obstructive Pulmonary Disease
PR NewswireTheravance Biopharma to Participate in an Upcoming Investor Conference
PR NewswireTheravance Biopharma, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update
PR NewswireTheravance Biopharma to Participate in an Upcoming Investor Conference
PR NewswireTheravance Biopharma to Report Second Quarter 2024 Financial Results on August 5, 2024
PR NewswireTheravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
PR NewswireTheravance Biopharma to Participate in an Upcoming Investor Conference
PR NewswireTheravance Biopharma to Report First Quarter 2024 Financial Results on May 13, 2024
PR NewswireTheravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients...
PR NewswireTheravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
PR NewswireTheravance Biopharma to Participate in an Upcoming Investor Conference

Theravance Biopharma News

Theravance Biopharma News: auf dieser Seite finden Sie alle Theravance Biopharma News und Nachrichten zur Theravance Biopharma Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Theravance Biopharma News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Theravance Biopharma News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.